New insider activity at Hims & Hers Health ( (HIMS) ) has taken place on March 28, 2025.
COO Melissa Baird has recently sold 67,687 shares of Hims & Hers Health stock, amounting to a total transaction value of $2,357,969.
Recent Updates on HIMS stock
In the last 24 hours, Hims & Hers Health experienced significant stock price movements due to several developments. BofA raised its price target for the company, citing accelerated GLP-1 sales growth, which suggests potential upside to market estimates. However, the FDA’s updated enforcement timelines for semaglutide and tirzepatide compounding have raised concerns. A Texas court ruling against the Outsourcing Facilities Association’s injunction related to tirzepatide is expected to negatively impact Hims & Hers, as it could lead to the cessation of bulk compounding of these drugs, affecting revenue projections. Consequently, Citi expects the stock to trade down, and premarket trading already shows a decline of 8%. Despite the challenges, app downloads for Hims & Hers surged by 47% year-over-year in February, driven by Hers downloads, indicating positive momentum in this area.
More about Hims & Hers Health
YTD Price Performance: 32.38%
Average Trading Volume: 22,147,997
Technical Sentiment Signal: Sell
Current Market Cap: $8.23B